Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

Cancer
R J MotzerM W Kattan

Abstract

In a randomized, phase 3 trial, sunitinib demonstrated superior efficacy over interferon-alfa as first-line therapy in patients with metastatic clear-cell renal cell carcinoma (RCC). On the basis of outcome data from that trial, the authors developed a nomogram for predicting the probability of 12-month progression-free survival for patients who received sunitinib therapy. Three-hundred seventy-five patients who received sunitinib in the phase 3 trial were the subject of the current analysis. Nomogram pretreatment predictor variables included corrected serum calcium levels, the number of metastatic sites, hemoglobin levels, prior nephrectomy, the presence of lung and liver metastases, thrombocytosis, Eastern Cooperative Oncology Group performance status, time from diagnosis to treatment, and serum levels of alkaline phosphatase and lactate dehydrogenase. Investigator-assessed progression-free survival was the predicted outcome endpoint. Internal validation of the nomogram consisted of quantification of the discrimination with the concordance index and assessment of calibration. One-hundred seventy-four of 375 patients (46%) who received sunitinib achieved an objective response, and the median progression-free survival was 10.8 ...Continue Reading

References

Dec 1, 1971·Clinica Chimica Acta; International Journal of Clinical Chemistry·D H Orrell
May 14, 1982·JAMA : the Journal of the American Medical Association·F E HarrellR A Rosati
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerJ Ferrara
Oct 3, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M W KattanS A Leibel
Jul 4, 2001·The Journal of Urology·M W KattanP Russo
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael W KattanMurray F Brennan
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Jan 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·W Marston LinehanLen Neckers
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tarek M MekhailRonald Bukowski
Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerBrian I Rini
Feb 9, 2006·British Journal of Cancer·P H PatelR J Motzer
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Robert J MotzerM Dror Michaelson
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J Motzer, Ronald M Bukowski
Dec 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Premal H PatelRobert J Motzer
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Mar 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laura Q M Chow, S Gail Eckhardt
May 12, 2007·European Urology·Paul C M S Verhagen
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial

❮ Previous
Next ❯

Citations

Apr 7, 2010·World Journal of Urology·Alessandro Volpe, Jean Jacques Patard
Nov 23, 2011·Current Urology Reports·Paul L Crispen, Michael L Blute
Jun 2, 2009·Nature Reviews. Clinical Oncology·Rakesh K JainA Gregory Sorensen
Apr 3, 2009·Current Opinion in Oncology·Jorge A GarciaPaul A Godley
Nov 1, 2009·Therapeutic Advances in Medical Oncology·Tanya B DorffDavid I Quinn
May 6, 2010·World Journal of Surgical Oncology·Astrid DalhaugCarsten Nieder
Mar 5, 2011·The Oncologist·David S FinleyArie S Belldegrun
Dec 4, 2009·Indian Journal of Urology : IJU : Journal of the Urological Society of India·John S P Yuen
Mar 31, 2012·Archives of Pathology & Laboratory Medicine·George J Netto, Liang Cheng
Aug 12, 2009·Future Oncology·Edmund ChiongVitaly Margulis
Jan 31, 2014·Medical Oncology·Maria StenmanMagnus Lindskog
May 27, 2009·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·Y Neuzillet, C Coulange
Jul 1, 2014·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·F-X NouhaudC Pfister
Mar 28, 2009·Current Opinion in Urology·Hendrik Isbarn, Pierre I Karakiewicz
Jul 2, 2010·Current Opinion in Urology·Maxine SunPierre I Karakiewicz
Jun 17, 2009·Current Opinion in Supportive and Palliative Care·Kevin G Kwan, Anil Kapoor
May 11, 2010·Journal of Cancer Research and Clinical Oncology·Manuela Schmidinger, Christoph C Zielinski
Jun 22, 2012·Expert Review of Anticancer Therapy·Axel Bex, Tom Powles
Dec 4, 2009·Expert Review of Anticancer Therapy·Nicola L AinsworthTim Eisen
Jun 6, 2009·Expert Review of Anticancer Therapy·Thomas KöpkeEdwin Herrmann
Jun 6, 2009·Expert Review of Anticancer Therapy·Stéphane OudardFlorian Scotte
Mar 13, 2015·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Daniel KeizmanRaanan Berger
Jun 19, 2012·Seminars in Cancer Biology·Rosalie FisherJames Larkin
May 12, 2012·European Urology·Malek MeskawiPierre I Karakiewicz
May 25, 2010·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Srinevas K ReddyRebekah R White
Jul 12, 2011·European Urology·Maxine SunPierre I Karakiewicz
Jul 19, 2011·Hematology/oncology Clinics of North America·Patricia A TangDaniel Y C Heng
Jul 20, 2011·Cancer Treatment Reviews·Jordi RemonSusana Martínez
Dec 7, 2010·Cancer Treatment Reviews·G Di LorenzoG Cartenì
Dec 7, 2010·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·F ArrouaC Bastide

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.